Document is current

Ruxolitinib as a therapy choice for refractory pruritus in a patient with essential thrombocythemia with CALR mutation

Crossref DOI link: https://doi.org/10.17352/2455-5282.000167

Published Online: 2023-01-25

Update policy: https://doi.org/10.17352/crossmark-policy